Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06259383
Status:
COMPLETED
Last Update Posted:
2024-02-14
First Post:
2024-01-26
Brief Title:
Oral Ivermectin for Chikungunya Viral Infection
Sponsor:
Prince of Songkla University
Organization:
Prince of Songkla University
Study Overview
Official Title:
A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chikungunya viral infection CVI is a mosquito-borne infection caused by chikungunya virus CHIKV an alphavirus belonging to the family Togaviridae This infection causes febrile illness associated with high fever rash acute deliberating and persistent arthralgia There is no licensed vaccine or specific treatment for this infection Ivermectin IVM commonly-used antiparasitic has been demonstrated to inhibit replication of CHIKV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None